CBCA (cannabichromenic acid) is the raw acid the plant turns into CBC (cannabichromene), and it doesn't intoxicate. Cannabis makes CBCA from CBGA, and heat decarboxylates it to CBC; that much is Established chemistry. What CBCA does in people is another story. Nobody has published a controlled human study of CBCA, which leaves the question untested rather than tested and null, and everything past the chemistry is catalogue in progress.
C22H30O4 · MW ≈ 358.47 · CAS 185505-15-1 · non-intoxicating raw acid · acid precursor of CBC · the third CBGA branch (via CBCA synthase) · decarboxylates to CBC (~110–160 °C)
Forms from CBGA. Becomes CBC.
40 questions, and 23 of them earn a verified grade on the six-rung evidence ladder. 13 carry an evidence state instead of a rung, and most of those read no primary evidence: our registry has no study on the question, a different finding from not supported and marked differently. The other 4 use an author qualifier still waiting to enter the controlled vocabulary. They appear without a grade chip until it does, rather than wear a guessed one.
CBGA, the parent acid, splits three ways in the plant. Two branches lead to THCA and CBDA and get all the attention; the third leads to CBCA and, once heat arrives, to CBC. The chemistry of that third branch is settled and graded as fact: what CBCA is, its formula and CAS number, the enzyme that builds it from CBGA, the heat that turns it into CBC, and a raw acid that doesn't get anyone high. Its biology is close to a blank sheet, so any effect or benefit is reported as a claim made by others, set beside its limits, and CBG Atlas does not make, adopt, or affirm these claims. Where the evidence runs out, we call it "catalogue in progress." Not medical or legal advice.
CBCA (cannabichromenic acid) is the raw acid the plant turns into CBC (cannabichromene), and it doesn't intoxicate. Cannabis makes CBCA from CBGA, and heat decarboxylates it to CBC; that much is Established chemistry. What CBCA does in people is another story. Nobody has published a controlled human study of CBCA, which leaves the question untested rather than tested and null, and everything past the chemistry is catalogue in progress.
CBCA is short for cannabichromenic acid, the carboxylic-acid ("-ic acid") precursor of cannabichromene (CBC). The "A" marks the acid group the living plant builds first, before heat turns CBCA into CBC. Formula C22H30O4, molecular weight ≈ 358.47, CAS 185505-15-1: Established chemistry, and all of it silent on what the molecule does.
From CBGA, the "mother acid", along one of three branches. An enzyme, CBCA synthase, converts CBGA to CBCA, running in parallel with the THCA and CBDA branches. Those neighbouring enzymes are imperfectly selective, too: the THCA and CBDA synthases make some CBCA of their own (Zirpel 2018, PMID 30053500).
Yes. The cannabis plant makes CBCA from CBGA, and it is the form present before anything is heated; neutral CBC mostly appears once heat, drying or ageing strips CO₂ from the acid. Labs can prepare CBCA as a reference standard, but the molecule in hemp is the plant's own work, a piece of Established plant chemistry.
No. CBCA is a raw cannabinoid acid, and those acids don't switch the CB1 receptor on the way THC does. CBC, which CBCA becomes on heating, doesn't intoxicate either, and verified evidence of CBCA producing a high in people is nowhere in the record.
CBCA isn't known to intoxicate, and neither is CBC, its heated form. Whether the raw acid has some subtler psychoactive effect is a question nobody has studied, which leaves it open rather than ruled out. Controlled human data on CBCA are absent in both directions, so that part of the question stays catalogue in progress.
Its effects in the body are not established. The one verified in-vitro finding for cannabinoid acids as a class is inhibition of the enzyme DAGLα (De Petrocellis 2011, PMID 21175579), a cell-level result, not an effect in people. Catalogue in progress.
Nobody has verified what raw CBCA does in people. It is a non-intoxicating acid with no established activity of its own, and the interest in "raw cannabinoids" has run well ahead of the evidence, since CBCA's raw effects are not established (not medical advice). Getting neutral CBC takes heat to decarboxylate the acid. Catalogue in progress.
That depends on where the CBCA came from and where you are; the molecule alone settles little. Where hemp-derived cannabinoids under 0.3% Δ⁹-THC are allowed, CBCA generally falls inside that framework, and elsewhere it may be restricted. This is a general snapshot dated 2026-07-11, not legal advice. Verify locally.
Generally yes, within one limit. Under the 2018 Farm Bill, hemp-derived CBCA in a product at or below 0.3% Δ⁹-THC by dry weight is generally federally legal as hemp. The limit is the FDA, which has not authorised cannabinoids as foods or dietary supplements, so a lawful hemp derivative can still be an unlawful food ingredient. For a brand weighing a gummy or a capsule, that second point is the one that bites. Dated 2026-07-11; general information, not legal advice.
It depends on your state. Some restrict hemp cannabinoids more tightly than federal law does, and because statutes almost never name CBCA, it usually inherits the state's general hemp and THC rules. Check the current statute or ask a qualified attorney. Dated 2026-07-11; informational only, not legal advice.
Generally not as a food or supplement anyone can sell freely. The EU and UK treat extracted cannabinoids as novel foods that need authorisation, CBCA holds none of its own, and Canada regulates isolated phytocannabinoids under the Cannabis Act. Rules vary by product class and change often, so check the current national position before relying on this. Dated 2026-07-11; general information, not legal advice.
None has been established. CBCA turns up in raw and full-spectrum products with benefit claims attached, yet verified human or preclinical evidence for any of them is missing, and CBG Atlas does not affirm them (not medical advice). For a brand, that makes every CBCA benefit claim a claim without evidence behind it, for now. Catalogue in progress.
CBCA is used mostly as an ingredient in raw-cannabinoid or full-spectrum products, and as a research and reference compound. It has no established therapeutic use. Its real job is biochemical: it is the acid that becomes CBC when heated (not medical advice). Catalogue in progress.
Not for CBCA. Some cannabinoids have shown antibacterial activity in laboratory studies, but that result belongs to them, and nobody has shown such an effect for CBCA in people or animals (not medical advice). An antibacterial claim on a CBCA label is borrowing from other molecules. We report the claim without affirming it. Catalogue in progress.
No. CBCA has never been tested in a controlled human trial, and that is an absence of testing rather than a negative result: with no study run, nothing has turned up for or against it in people. The verified data stop at cell-level observations of cannabinoid acids, so CBG Atlas lists CBCA as catalogue in progress and claims no effect for it.
Nobody has established that. CBCA has no human safety studies, no defined dose and no long-term data, so the accurate word is untested: an open question, not a clean bill of health. Failing to get you high and being safe are different properties. Consult a qualified professional before use, especially if you take other medications. Catalogue in progress. (Not medical advice.)
CBCA's side effects are unknown. No controlled study has documented its adverse effects, and a lack of data is no evidence of safety. Products can also carry other cannabinoids or contaminants. If you feel unwell, stop and seek advice (not medical advice). Catalogue in progress.
Nobody can say. With no safe or effective CBCA dose defined and no overdose data, "too much" has nothing to be measured against. With any unstudied compound, more is a bigger unknown rather than a better result. This is not dosing or medical advice. Catalogue in progress.
Nobody knows. CBCA's interactions are untested, in people and in the lab alike. Cannabinoids as a class can affect the enzymes that metabolise drugs, which makes an interaction plausible, and plausible is a long way from demonstrated. If you take any medication, ask a clinician or pharmacist before use. Catalogue in progress. (Not medical advice.)
Probably not. Standard drug tests look for THC's metabolite (THC-COOH), and CBCA neither is that metabolite nor turns into THC, so direct interference is unlikely. The real variable is trace THC in the hemp product. Cross-reactivity data specific to CBCA are limited, and a current third-party certificate of analysis is the only way to see what a product contains.
No. CBCA is a different molecule, and heat turns it into non-intoxicating CBC rather than THC; pure CBCA contains no THC, as a matter of Established chemistry. The product is what varies. Hemp-derived goods can carry trace Δ⁹-THC unless they are made from isolate, so read the batch certificate of analysis (COA) rather than the front label.
CBCA itself is an unlikely culprit. Drug tests look elsewhere, and CBCA forms no THC. The risk sits with trace THC in a hemp product, so anyone who is drug-tested should choose products whose COA shows non-detectable THC.
CBCA is taken mostly in raw or full-spectrum hemp preparations, or as a reference isolate, because heat turns it into CBC. It may be used sublingually or as part of a raw-cannabinoid blend. Those are formats; no route or dose for CBCA has been studied (not medical advice).
Few. CBCA turns up in some raw or full-spectrum extracts and in reference isolates for labs, while standalone consumer products are uncommon. Heating any product converts its CBCA to CBC. Potency and purity vary, so a third-party certificate of analysis (COA) matters.
CBCA has no established dose. No clinical study has defined a safe or effective amount, so any figure on a label is the manufacturer's choice rather than a number drawn from evidence, and CBG Atlas offers no dosing guidance. Consult a qualified professional (not medical or dosing advice). Catalogue in progress.
Only if you want CBC. Heat decarboxylates CBCA and drives off CO₂, roughly in the 110–160 °C range. Left raw, CBCA stays a non-intoxicating acid whose own effects nobody has studied. For a formulator, every heated processing step moves CBCA toward CBC, so the form you want decides how the product is made.
CBCA is the raw acid in the plant; CBC is the neutral form left after heating (decarboxylation). Neither intoxicates. One carboxyl group separates them, and it leaves as CO₂ when CBCA is heated. CBC gets somewhat more attention, though verified human evidence is thin for both.
CBGA is the parent, CBCA one of its offspring. CBGA, the "mother acid", sits upstream, and CBCA is one of its three branch products (made by CBCA synthase), alongside THCA and CBDA. Both are non-intoxicating pentyl-series acids, and both decarboxylate to their neutral forms.
They are sibling acids, all made from CBGA on the pentyl line. CBCA is the chromene-branch acid (→CBC), while THCA (→THC) and CBDA (→CBD) form the other two branches. Their propyl counterparts are the varin acids THCVA, CBDVA and CBGVA. Raw, all of them are non-intoxicating, and heat decarboxylates each to its neutral cannabinoid.
Yes, they are different molecules. "Raw" means the acid, CBCA, is intact and non-intoxicating; "decarbed" means heat has removed its carboxyl group, leaving neutral CBC. Only decarbed material is CBC, an Established relationship. Neither form is an approved or established treatment for anything, and the human evidence for both is catalogue in progress. (Not medical advice.)
CBCA's formula is C22H30O4, with a molecular weight of ≈ 358.47 g/mol and CAS number 185505-15-1. It is the carboxylic-acid precursor of CBC (C21H30O2) and a direct branch product of CBGA, carrying a carboxyl group that neutral CBC lacks; heat removes that group as CO₂ and leaves CBC. The chemical identity is Established. What CBCA does biologically is a separate, largely unstudied question.
CBCA is extracted from raw, unheated cannabis with gentle methods that avoid heat, since heat converts it to CBC, and then purified by chromatography. The plant usually holds only a minor share of it and heat destroys it, so isolating stable CBCA gives low yields and demands real technical care, which goes a long way to explaining why finished CBCA products are rare. The extraction chemistry is Established.
Yes. CBCA is one of three branches off CBGA: CBCA synthase converts CBGA to CBCA, alongside the THCA and CBDA branches, and the THCA and CBDA synthases, being imperfectly selective, also make some CBCA from CBGA (Zirpel 2018). Its place on the biosynthetic tree is verified.
Roughly 110–160 °C, as with other cannabinoid acids, and the conversion takes time. Gentler heat is slower and cleaner; hotter is faster but risks degrading the material. Decarboxylation kinetics specific to CBCA are less well published (catalogue in progress).
From a small number of specialty hemp, cannabinoid and reference-chemical suppliers, usually as raw extracts or reference isolates. Stock is irregular, as you would expect of a niche product. CBG Atlas endorses no brand; buy only from vendors who publish third-party lab results.
Because the plant makes little of it and heat takes it away. CBCA is usually a minor component, almost any heat converts it to CBC, and isolating a stable supply gives low yields and is technically demanding. Cold handling, cold storage and extra purification all add cost, which is why it sells dear next to plentiful cannabinoids like CBD. Scarcity reflects supply and says nothing about potency.
Ask for a current certificate of analysis (COA) from an accredited third-party lab. It should confirm the CBCA content, show the THC level and screen for pesticides, solvents and heavy metals, and the label should match it. A missing or mismatched COA is a red flag.
Your decision. CBCA has no established benefit and has never been tested in a controlled human trial, so any value is speculative: untested, a different state from tested and rejected. Catalogue in progress. If you try it, choose lab-tested products with a current certificate of analysis and keep your expectations level with the evidence. (Not medical advice.)
A third-party COA that matches the label, a compliant and clearly declared THC level, stated cannabinoid amounts, contaminant screening and transparent sourcing. Treat any health claim attached to CBCA with suspicion: none is verified, and its evidence file reads catalogue in progress. At the point of sale, testing and transparency are what you can actually check. (Not medical advice.)
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Educational, not medical or legal advice. Statements about effects, benefits or uses report claims made by third parties. CBG Atlas does not make, adopt or affirm them. Legal status depends on jurisdiction, product class and date, and it changes, so check it against the official source. See how we grade and the safety page.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Families
Its acid or neutral form
Head-to-head